Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Comprehensive Cancer Center of Wake Forest University Identifier:
First received: January 16, 2006
Last updated: July 12, 2012
Last verified: July 2012

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel works in treating patients with recurrent stage III or stage IV non-small cell lung cancer.

Condition Intervention Phase
Lung Cancer
Drug: docetaxel
Drug: gemcitabine hydrochloride
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Taxotere and Gemcitabine for Stages III-B and IV Non-Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Comprehensive Cancer Center of Wake Forest University:

Primary Outcome Measures:
  • patient response rate to weekly taxotere and gemcitabine [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluate toxicity of weekly Taxotere and Gemcitabine [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 49
Study Start Date: November 2000
Study Completion Date: September 2007
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: docetaxel
    40 milligrams per meter squared infused over 30 minutes on day 1 and 8, repeated every 21 days
    Drug: gemcitabine hydrochloride
    800 milligrams per meter squared intraveneously for two consecutive weeks followe by one week of no treatment then repeated.
Detailed Description:



  • Determine the response rate of patients with recurrent stage IIIB and IV non-small cell lung cancer treated with gemcitabine hydrochloride and docetaxel.
  • Determine the overall and progression-free survival of patients treated with this regimen.
  • Determine the toxic effects of this regimen in these patients.


  • Determine the duration of response in patients treated with this regimen.

OUTLINE: Patients receive gemcitabine hydrochloride IV over 30 minutes followed by docetaxel IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for survival.

PROJECTED ACCRUAL: A total of 51 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed stage IIIB or IV non-small cell lung cancer, including any of the following types:

    • Squamous cell carcinoma
    • Adenocarcinoma, including bronchoalveolar cell adenocarcinoma
    • Large cell anaplastic carcinoma, including giant and clear cell carcinomas
  • Histologic or cytologic documentation of recurrence is required
  • Measurable or evaluable disease, defined as any mass reproducibly measurable in 2 perpendicular diameters by physical examination or imaging

    • The following lesions are not considered measurable or evaluable:

      • Bone disease only
      • Pleural or pericardial effusions
      • Previously irradiated lesions, unless subsequent progression is documented
  • CNS metastases allowed provided the patient undergoes at least 2 weeks of radiotherapy prior to study entry


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • Negative pregnancy test
  • CALGB performance status ≤ 1
  • Life expectancy ≥ 3 months
  • Granulocyte count > 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Creatinine ≤ 2 times normal
  • Bilirubin normal
  • SGOT and/or SGPT ≤ 2.5 times upper limit of normal (ULN) AND alkaline phosphatase ≤ 1.5 times ULN OR
  • Alkaline phosphatase 4 times ULN and SGOT and/or SGPT normal
  • Ejection fraction normal by ECHO or MUGA
  • No history of congestive heart failure
  • No psychiatric illness that would preclude study compliance
  • No serious medical or psychiatric illness that would preclude giving informed consent or limit survival to < 3 months
  • No active uncontrolled bacterial, fungal, or viral infection
  • No other malignancy within the past 5 years except curatively treated carcinoma in situ of the cervix or breast, basal cell or squamous carcinoma of the skin, or other surgically resected non-recurrent primary tumor not treated with adjuvant radiotherapy or chemotherapy
  • No pre-existing peripheral neuropathy ≥ grade 2


  • At least 2 weeks since prior major surgery and recovered from acute effects
  • At least 2 weeks since prior palliative radiotherapy and recovered from acute toxic effects

    • Any persistent toxicity (e.g., alopecia or hyperpigmentation) not associated with clinical morbidity allowed
  • No prior chemotherapy
  • No concurrent cranial or thoracic radiation therapy
  • No concurrent cytotoxic or hormonal therapy
  • Concurrent palliative radiotherapy allowed for relief of localized pain and obstruction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00278460

Sponsors and Collaborators
Comprehensive Cancer Center of Wake Forest University
National Cancer Institute (NCI)
Study Chair: Antonius A. Miller, MD Comprehensive Cancer Center of Wake Forest University
  More Information

Responsible Party: Comprehensive Cancer Center of Wake Forest University Identifier: NCT00278460     History of Changes
Other Study ID Numbers: CDR0000462116  CCCWFU-62199  AVENTIS-CCCWFU-62199  AG-CCCWFU-62199  CCCWFU-BG99-322 
Study First Received: January 16, 2006
Last Updated: July 12, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Comprehensive Cancer Center of Wake Forest University:
stage IIIB non-small cell lung cancer
stage IV non-small cell lung cancer
adenocarcinoma of the lung
bronchoalveolar cell lung cancer
large cell lung cancer
recurrent non-small cell lung cancer
squamous cell lung cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on May 26, 2016